Belgium-based healthtech company Nyxoah has undertaken an IPO on the Euronext stock exchange in Europe and attracted €85 million.
Source: Euronext blog
Founded in Israel in 2009 by Robert Taub, the current Executive Chairman, Nyxoah is a medical device company focused on the development and commercialization of hypoglossal nerve stimulation (HGNS) therapy to treat sleep disordered breathing conditions. It is the first Belgian company graduated from Euronext’s pre-IPO TechShare programme.
As reported by Globes, after Nyxoah went public, its share price has risen by 14% pushing the company’s valuation to €413 million and making it join the franchise of the 89 life science companies listed on Euronext’s markets.
Nyxoah is planning to use the raised capital to conduct clinical trials in the US, Europe and Australia, and to fund product development, R&D, marketing strategy and commercialization, the company tells.
